2024
Presence of Mood and/or Anxiety Disorders Does Not Affect Success of Weight Management Therapies in Metabolic Dysfunction-Associated Steatotic Liver Disease
Bollinger B, Cotter R, Deng Y, Ilagan-Ying Y, Gupta V. Presence of Mood and/or Anxiety Disorders Does Not Affect Success of Weight Management Therapies in Metabolic Dysfunction-Associated Steatotic Liver Disease. Digestive Diseases And Sciences 2024, 1-8. PMID: 39604664, DOI: 10.1007/s10620-024-08724-y.Peer-Reviewed Original ResearchTotal body weight lossBody weight lossPhentermine-topiramateBariatric surgeryHepatology practiceWeight lossAnxiety disordersLiver diseaseSteatotic liver diseaseFIB-4 scorePredictors of weight lossPresence of psychiatric diseaseRetrospective cohort studyMultivariate logistic regression modelWeight management therapySignificant predictorsHepatic outcomesFIB-4Logistic regression modelsCohort studyICD-10 diagnosisPatient populationPresence of moodPrimary outcomeSecondary outcomes
2019
Medical Approach for Weight Loss in Nonalcoholic Fatty Liver Disease
Do A, Ilagan-Ying Y, Mehal W. Medical Approach for Weight Loss in Nonalcoholic Fatty Liver Disease. Current Hepatology Reports 2019, 18: 444-454. DOI: 10.1007/s11901-019-00498-6.Peer-Reviewed Original ResearchSuccessful weight lossFatty liver diseaseWeight lossLiver diseaseReviewNonalcoholic fatty liver diseaseNonalcoholic fatty liver diseaseWeight loss medicationsCurrent medical therapyPatient-centered approachMedical therapyPatient weightPatient evaluationMultisystemic complicationsEpidemic proportionsBehavioral change goalsNAFLDMedical approachObesityDiseaseMedicationsMultimodal approachFibrosisTreatmentSteatosisComplications